Trial Profile
Use of rituximab in opsoclonus-myoclonus in children with neuroblastoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Myoclonus; Neuroblastoma
- Focus Therapeutic Use
- 04 Jan 2021 Status changed from recruiting to discontinued.( Closed early due to low accrual)
- 01 Mar 2006 New trial record.